Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: A Population-Based Study

Xiaoyi Lin,1,2,&ast; Xin Lin,1,3,&ast; Yingzi Li,1,2,&ast; Yuchen Zhang,1,4 Jiali Lin,1 Guochun Zhang1 1Department of Breast Cancer, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, People’s Republic of China; 2Shantou University Medica...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Lin X, Li Y, Zhang Y, Lin J, Zhang G
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	breast cancer her2 second primary malignancy incidence seer Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/ff4c8d40c6c64235a67013e13263b7f4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ff4c8d40c6c64235a67013e13263b7f4
record_format	dspace
spelling	oai:doaj.org-article:ff4c8d40c6c64235a67013e13263b7f42021-11-23T18:43:01ZDifferential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: A Population-Based Study1178-7074https://doaj.org/article/ff4c8d40c6c64235a67013e13263b7f42021-11-01T00:00:00Zhttps://www.dovepress.com/differential-second-primary-malignancy-occurrence-after-breast-cancer--peer-reviewed-fulltext-article-IJGMhttps://doaj.org/toc/1178-7074Xiaoyi Lin,1,2,&ast; Xin Lin,1,3,&ast; Yingzi Li,1,2,&ast; Yuchen Zhang,1,4 Jiali Lin,1 Guochun Zhang1 1Department of Breast Cancer, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, People’s Republic of China; 2Shantou University Medical College, Shantou, Guangdong, People’s Republic of China; 3The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, People’s Republic of China; 4School of Medicine, South China University of Technology, Guangzhou, Guangdong, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Guochun ZhangDepartment of Breast Cancer, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Yuexiu District, Guangzhou, 510080, Guangdong, People’s Republic of ChinaTel/Fax +86 20-83827812-50910Email zhangguochun@gdph.org.cnPurpose: Our study aims to analyze the association between HER2 status of breast cancer (BC) and second primary malignancy (SPM) occurrence.Materials and Methods: Based on BC patients registered between 2010 and 2018 in the NCI SEER database, we utilized standardized incidence ratio (SIR) and Poisson regression to quantify SPM occurrence compared with the general population. Then, adjusted for competing death risk, cumulative incidence function and Gray’s test were adopted to estimate the probability of SPM. Subsequent proportional subdistribution hazards regression was executed to identify the HER2 status impact on SPM risk. Finally, survival analysis was performed.Results: A total of 409,796 first BC patients were included and 18,283 were identified with at least one SPM. The SIR of SPM after HER2+ BC was significantly lower than HER2- BC (1.03 vs 1.13; RR, 0.92; 95% CI, 0.88– 0.96; p< 0.001). The predominantly declining SPM risk was only observed for second BC (RR, 0.89; 95% CI, 0.82– 0.96; p=0.003) and lung cancer (RR, 0.84; 95% CI, 0.74– 0.95; p=0.007). Furthermore, competing risk analysis verified the protective effect of HER2 positivity status on SPM occurrence. The 5-year cumulative incidence of SPM following HER2+ and HER2- BC were 4.09% and 5.16%, respectively (p< 0.001). In addition, among patients suffering from SPM, HER2 positivity status contributed to better overall survival.Conclusion: It is demonstrated that HER2+ BC patients had lower SPM incidence, which was remarkable for second BC and lung cancer.Keywords: breast cancer, HER2, second primary malignancy, incidence, SEERLin XLin XLi YZhang YLin JZhang GDove Medical Pressarticlebreast cancerher2second primary malignancyincidenceseerMedicine (General)R5-920ENInternational Journal of General Medicine, Vol Volume 14, Pp 8775-8784 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer her2 second primary malignancy incidence seer Medicine (General) R5-920
spellingShingle	breast cancer her2 second primary malignancy incidence seer Medicine (General) R5-920 Lin X Lin X Li Y Zhang Y Lin J Zhang G Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: A Population-Based Study
description	Xiaoyi Lin,1,2,&ast; Xin Lin,1,3,&ast; Yingzi Li,1,2,&ast; Yuchen Zhang,1,4 Jiali Lin,1 Guochun Zhang1 1Department of Breast Cancer, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, People’s Republic of China; 2Shantou University Medical College, Shantou, Guangdong, People’s Republic of China; 3The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, People’s Republic of China; 4School of Medicine, South China University of Technology, Guangzhou, Guangdong, People’s Republic of China&ast;These authors contributed equally to this workCorrespondence: Guochun ZhangDepartment of Breast Cancer, Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences, 106 Zhongshan Er Road, Yuexiu District, Guangzhou, 510080, Guangdong, People’s Republic of ChinaTel/Fax +86 20-83827812-50910Email zhangguochun@gdph.org.cnPurpose: Our study aims to analyze the association between HER2 status of breast cancer (BC) and second primary malignancy (SPM) occurrence.Materials and Methods: Based on BC patients registered between 2010 and 2018 in the NCI SEER database, we utilized standardized incidence ratio (SIR) and Poisson regression to quantify SPM occurrence compared with the general population. Then, adjusted for competing death risk, cumulative incidence function and Gray’s test were adopted to estimate the probability of SPM. Subsequent proportional subdistribution hazards regression was executed to identify the HER2 status impact on SPM risk. Finally, survival analysis was performed.Results: A total of 409,796 first BC patients were included and 18,283 were identified with at least one SPM. The SIR of SPM after HER2+ BC was significantly lower than HER2- BC (1.03 vs 1.13; RR, 0.92; 95% CI, 0.88– 0.96; p< 0.001). The predominantly declining SPM risk was only observed for second BC (RR, 0.89; 95% CI, 0.82– 0.96; p=0.003) and lung cancer (RR, 0.84; 95% CI, 0.74– 0.95; p=0.007). Furthermore, competing risk analysis verified the protective effect of HER2 positivity status on SPM occurrence. The 5-year cumulative incidence of SPM following HER2+ and HER2- BC were 4.09% and 5.16%, respectively (p< 0.001). In addition, among patients suffering from SPM, HER2 positivity status contributed to better overall survival.Conclusion: It is demonstrated that HER2+ BC patients had lower SPM incidence, which was remarkable for second BC and lung cancer.Keywords: breast cancer, HER2, second primary malignancy, incidence, SEER
format	article
author	Lin X Lin X Li Y Zhang Y Lin J Zhang G
author_facet	Lin X Lin X Li Y Zhang Y Lin J Zhang G
author_sort	Lin X
title	Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: A Population-Based Study
title_short	Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: A Population-Based Study
title_full	Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: A Population-Based Study
title_fullStr	Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: A Population-Based Study
title_full_unstemmed	Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: A Population-Based Study
title_sort	differential second primary malignancy occurrence after breast cancer according to her2 status: a population-based study
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/ff4c8d40c6c64235a67013e13263b7f4
work_keys_str_mv	AT linx differentialsecondprimarymalignancyoccurrenceafterbreastcanceraccordingtoher2statusapopulationbasedstudy AT linx differentialsecondprimarymalignancyoccurrenceafterbreastcanceraccordingtoher2statusapopulationbasedstudy AT liy differentialsecondprimarymalignancyoccurrenceafterbreastcanceraccordingtoher2statusapopulationbasedstudy AT zhangy differentialsecondprimarymalignancyoccurrenceafterbreastcanceraccordingtoher2statusapopulationbasedstudy AT linj differentialsecondprimarymalignancyoccurrenceafterbreastcanceraccordingtoher2statusapopulationbasedstudy AT zhangg differentialsecondprimarymalignancyoccurrenceafterbreastcanceraccordingtoher2statusapopulationbasedstudy
_version_	1718416192275742720

Differential Second Primary Malignancy Occurrence After Breast Cancer According to HER2 Status: A Population-Based Study

Ejemplares similares